| Autor: | Gaylen M. Zentner, Gregory A. McClelland, Gerald S. Rork, James D. Pipkin, Lida Liu, Amy R. Coulter, J. Douglas Rogers, Michael S. Schwartz, Steven C. Sutton, Raju D. Amin, Jules I. Schwartz, Yale B. Mitchel, Haiyung Cheng, Chung Y. Lui, Kenneth Grasing, David L. Ebel, Karen Engle |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Pharmacology
biology Organic Chemistry Pharmaceutical Science Sustained release dosage forms Reductase Controlled release Hydroxymethylglutaryl-CoA reductase Enzyme inhibitor Simvastatin HMG-CoA reductase medicine biology.protein Molecular Medicine Pharmacology (medical) Lovastatin Biotechnology medicine.drug |
| Zdroj: | Pharmaceutical Research. 10:1683-1687 |
| ISSN: | 0724-8741 |
| DOI: | 10.1023/a:1018997308946 |
| Popis: | Seven sustained/controlled-release dosage forms were designed for gastrointestinal delivery of lovastatin or simvastatin, two potent HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. The in vivo performance of these formulations was evaluated in dogs and healthy volunteers in terms of the cholesterol lowering efficacy and/or systemic concentrations of HMG-CoA reductase inhibitors. Results from the present and previous studies suggest that, through the controlled release of HMG-CoA reductase inhibitors, sustained lower plasma concentrations of HMG-CoA reductase inhibitors may result in an equal or better therapeutic efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink